AIMS: It has been demonstrated that inhibition of endothelium derived nitric oxide with NG-monomethyl-L-arginine (L-NMMA) results in a different cardiac and peripheral vascular response. The purpose of this study was to investigate the pharmacokinetic-pharmacodynamic profile of L-NMMA and pharmacokinetic interactions with L-arginine in healthy subjects. METHODS: Plasma pharmacokinetics were analysed from two different studies: In study 1, 3 mg kg-1 L-NMMA was administered i.v. over 5 min and systemic haemodynamics, cardiac output (CO), fundus pulsation amplitude (FPA), and NO-exhalation (exhNO) were measured at baseline and 15, 65, 95, 155, and 305 min after start of drug administration (n=7). In study 2, 17 mg kg-1 min-1 of the physiologic substrate for nitric oxide synthase, L-arginine, was coinfused i.v. over 30 min with a primed constant infusion of 50 microg kg-1 min-1 L-NMMA (n=8). RESULTS: Bolus infusion of L-NMMA resulted in a maximum plasma concentration of 12. 9+/-3.4 microg ml-1 (mean+/-s.d.) with elimination half-life of 63. 5+/-14.5 min and clearance of 12.2+/-3.5 ml min-1 kg-1 and caused a small hypertensive response, decreased CO by 13%, FPA by 26%, exhNO by 46% and increased systemic vascular resistance by 16% (P<0.05 each) 15 min after start of drug administration. Although only limited data points were available in the L-NMMA plasma concentration range between 0 and 4 microg ml-1, drug effects over time were in good agreement with an Emax model (r2>0.98 each), which also suggested that concentrations producing half-maximum effects were higher for FPA than for CO and exhNO. The coinfusion with L-arginine caused a nearly two-fold increase in plasma L-NMMA levels, indicating a pharmacokinetic interaction. CONCLUSIONS: In the absence of a systemic hypertensive response, L-NMMA significantly decreased CO, exhNO, and FPA. The concentration calculated to produce a half maximal effect was equivalent for exhNO and CO, but markedly higher for FPA. Furthermore, measurement of FPA is susceptible to changes in L-NMMA levels at small plasma concentrations.
AIMS: It has been demonstrated that inhibition of endothelium derived nitric oxide with NG-monomethyl-L-arginine (L-NMMA) results in a different cardiac and peripheral vascular response. The purpose of this study was to investigate the pharmacokinetic-pharmacodynamic profile of L-NMMA and pharmacokinetic interactions with L-arginine in healthy subjects. METHODS: Plasma pharmacokinetics were analysed from two different studies: In study 1, 3 mg kg-1 L-NMMA was administered i.v. over 5 min and systemic haemodynamics, cardiac output (CO), fundus pulsation amplitude (FPA), and NO-exhalation (exhNO) were measured at baseline and 15, 65, 95, 155, and 305 min after start of drug administration (n=7). In study 2, 17 mg kg-1 min-1 of the physiologic substrate for nitric oxide synthase, L-arginine, was coinfused i.v. over 30 min with a primed constant infusion of 50 microg kg-1 min-1 L-NMMA (n=8). RESULTS: Bolus infusion of L-NMMA resulted in a maximum plasma concentration of 12. 9+/-3.4 microg ml-1 (mean+/-s.d.) with elimination half-life of 63. 5+/-14.5 min and clearance of 12.2+/-3.5 ml min-1 kg-1 and caused a small hypertensive response, decreased CO by 13%, FPA by 26%, exhNO by 46% and increased systemic vascular resistance by 16% (P<0.05 each) 15 min after start of drug administration. Although only limited data points were available in the L-NMMA plasma concentration range between 0 and 4 microg ml-1, drug effects over time were in good agreement with an Emax model (r2>0.98 each), which also suggested that concentrations producing half-maximum effects were higher for FPA than for CO and exhNO. The coinfusion with L-arginine caused a nearly two-fold increase in plasma L-NMMA levels, indicating a pharmacokinetic interaction. CONCLUSIONS: In the absence of a systemic hypertensive response, L-NMMA significantly decreased CO, exhNO, and FPA. The concentration calculated to produce a half maximal effect was equivalent for exhNO and CO, but markedly higher for FPA. Furthermore, measurement of FPA is susceptible to changes in L-NMMA levels at small plasma concentrations.
Authors: L Schmetterer; S Dallinger; O Findl; K Strenn; U Graselli; H G Eichler; M Wolzt Journal: Invest Ophthalmol Vis Sci Date: 1998-06 Impact factor: 4.799
Authors: L Schmetterer; K Krejcy; J Kastner; M Wolzt; G Gouya; O Findl; F Lexer; H Breiteneder; A F Fercher; H G Eichler Journal: Exp Eye Res Date: 1997-03 Impact factor: 3.467
Authors: Alfredo Gamboa; Luis E Okamoto; André Diedrich; Leena Choi; David Robertson; Ginnie Farley; Sachin Paranjape; Italo Biaggioni Journal: Am J Physiol Heart Circ Physiol Date: 2012-01-27 Impact factor: 4.733
Authors: Jacqueline K Limberg; Katherine R Malterer; J Mikhail Kellawan; William G Schrage; Brad W Wilkins; Wayne T Nicholson; John H Eisenach; Michael J Joyner; Timothy B Curry Journal: Eur J Appl Physiol Date: 2016-12-24 Impact factor: 3.078
Authors: Hima Vedam; Craig L Phillips; David Wang; David J Barnes; Jan A Hedner; Gunnar Unger; Ronald R Grunstein Journal: Eur J Appl Physiol Date: 2008-09-25 Impact factor: 3.078
Authors: Andrew C Kithas; Ryan M Broxterman; Joel D Trinity; Jayson R Gifford; Oh Sung Kwon; Jay R Hydren; Ashley D Nelson; Jacob E Jessop; Amber D Bledsoe; David E Morgan; Russell S Richardson Journal: Nitric Oxide Date: 2020-09-24 Impact factor: 4.427
Authors: Taiming Liu; Meijuan Zhang; George T Mukosera; Dan Borchardt; Qian Li; Trent E Tipple; Abu Shufian Ishtiaq Ahmed; Gordon G Power; Arlin B Blood Journal: Redox Biol Date: 2019-06-04 Impact factor: 11.799